FDA advisers back Alzheimer's drug to slow disease

WASHINGTON, D.C. — A closely watched Alzheimer's drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment's expected approval for people with mild dementia caused by the brain-robbing disease.Food and Drug Administration advisers voted unanimously that the drug's ability to slow the disease outweighs its risks, including side effects like brain swelling and bleeding that will have to be monitored.

At a high level, Lilly's results mirrored those of Leqembi, with both medications showing a modest slowing of cognitive problems in patients with early-stage Alzheimer's. The Indianapolis-based company conducted a 1,700-patient study showing patients who received monthly IV infusions of its drug declined about 35% more slowly than those who got a sham treatment.The FDA had been widely expected to approve the drug in March.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Alzheimer's drug that can slow disease gets backing from FDA advisersWASHINGTON (AP) — A closely watched Alzheimer's drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment's expected approval for people with mild dementia caused by the brain-robbing disease.
Source: manilabulletin - 🏆 25. / 51 Read more »

Unilab lauds FDA’s proactive measures vs fake drugsPharmaceutical and healthcare company Unilab Inc. lauded the Food and Drug Administration (FDA) for taking proactive measures to protect the public from the perils of purchasing fake medicines.
Source: PhilstarNews - 🏆 1. / 94 Read more »